Cargando…
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396426/ https://www.ncbi.nlm.nih.gov/pubmed/25897200 http://dx.doi.org/10.2147/OPTH.S80784 |
_version_ | 1782366578233311232 |
---|---|
author | Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter |
author_facet | Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter |
author_sort | Kaja, Simon |
collection | PubMed |
description | The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision. |
format | Online Article Text |
id | pubmed-4396426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43964262015-04-20 Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter Clin Ophthalmol Original Research The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision. Dove Medical Press 2015-04-07 /pmc/articles/PMC4396426/ /pubmed/25897200 http://dx.doi.org/10.2147/OPTH.S80784 Text en © 2015 Kaja et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kaja, Simon Shah, Anna A Haji, Shamim A Patel, Krishna B Naumchuk, Yuliya Zabaneh, Alexander Gerdes, Bryan C Kunjukunju, Nancy Sabates, Nelson R Cassell, Michael A Lord, Ron K Pikey, Kevin P Poulose, Abraham Koulen, Peter Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
title | Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
title_full | Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
title_fullStr | Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
title_full_unstemmed | Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
title_short | Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
title_sort | nampt/pbef/visfatin serum levels: a new biomarker for retinal blood vessel occlusions |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396426/ https://www.ncbi.nlm.nih.gov/pubmed/25897200 http://dx.doi.org/10.2147/OPTH.S80784 |
work_keys_str_mv | AT kajasimon namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT shahannaa namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT hajishamima namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT patelkrishnab namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT naumchukyuliya namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT zabanehalexander namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT gerdesbryanc namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT kunjukunjunancy namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT sabatesnelsonr namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT cassellmichaela namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT lordronk namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT pikeykevinp namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT pouloseabraham namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions AT koulenpeter namptpbefvisfatinserumlevelsanewbiomarkerforretinalbloodvesselocclusions |